{"url_path":"/sec/avns/8-k/2026-07-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1606498/0001606498-26-000093-index.html","accession_number":"0001606498-26-000093","cik":"0001606498","ticker":"AVNS","issuer_name":"AVANOS MEDICAL, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1606498/0001606498-26-000093-index.html","primary_entity_key":"0001606498","primary_entity_name":"AVANOS MEDICAL, INC."},"word_count":689,"has_tables":true,"body_markdown":"Item 9.01    Financial Statements and Exhibits\n\n(d)Exhibits.\n\nExhibit No.Description\n\n104Cover Page Interactive Data File (embedded within the inline XBRL document)\n\nCautionary Forward-Looking Statements\n\nThis Current Report on Form 8-K contains information that includes or is based on “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “will,” and similar expressions. These “forward-looking statements” include statements about the pending acquisition and related transactions. Forward-looking statements are based on the current plans and expectations of Avanos’s management and are subject to various risks and uncertainties that could cause Avanos’s actual plan and results to differ materially from those expressed or implied in such statements. Such factors include: (i) uncertainties as to the timing of the acquisition, (ii) the possibility that competing acquisition proposals will be made; (iii) the possibility that Avanos will terminate the merger agreement to enter into an alternative transaction; (iv) the possibility that various closing conditions for the transactions contemplated by the merger\n\nagreement may not be satisfied or waived; (v) the risk that the merger agreement may be terminated in circumstances requiring Avanos to pay a termination fee; (vi) the potential impact of the announcement or consummation of the proposed transactions on Avanos’ relationships, including with employees, suppliers and customers; and (vii) the other factors and financial, operational and legal risks or uncertainties described in Avanos’ public filings with the SEC, including the “Risk Factors” section of Avanos’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as well as the Definitive Proxy Statement. The information contained herein speaks only as of the date of this Current Report on Form 8-K, and Avanos undertakes no obligation to update forward-looking statements, except as may be required by the securities laws.\n\nAdditional Information and Where to Find It\n\nIn connection with the Merger, Avanos has filed the Definitive Proxy Statement and other materials with the SEC. Avanos may file or furnish other documents with the SEC regarding the Merger. INVESTORS AND STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, THE ACCOMPANYING PROXY CARD, AND THE OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY BECOME AVAILABLE, AS THEY CONTAIN (OR WILL CONTAIN) IMPORTANT INFORMATION.\n\nStockholders may obtain free copies of the Definitive Proxy Statement, any amendments or supplements to the Definitive Proxy Statement and other documents filed by Avanos with the SEC for no charge at the SEC's website at www.sec.gov. Copies will also be available at no charge at the Investors section of the Avanos’ website at www.avanos.com.\n\nParticipants in the Solicitation\n\nAvanos, and its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from Avanos’ stockholders in connection with the Merger under the rules of the SEC. Detailed information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, are set forth in the Definitive Proxy Statement and other relevant documents filed with the SEC in connection with the Merger as they become available. Information regarding the direct and indirect beneficial ownership of the Avanos’ directors and executive officers in its securities is included in their SEC filings on Forms 3, 4 and 5, and additional information can also be found in Avanos’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 24, 2026 and its definitive proxy statement for its 2026 annual meeting of stockholders filed with the SEC on March 12, 2026.\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n    \n\nAVANOS MEDICAL, INC.\n\nDate:July 14, 2026By:/s/ John S. Fischer\n\nJohn S. Fischer\nVice President, Head of Legal and Secretary"}